In addition, the decline in overall obesity rate reported by the CDC isn’t the first such drop. Between 1999 and 2018, the ...
The consumer demand for injectable medications to control diabetes and aid weight loss isn't slowing down. And that's going ...
Could popular anti-obesity medications have an impact on alcohol misuse? KYW medical editor Dr. Brian McDonough has more from ...
The FDA put both peptides on its shortage list in 2022. Semaglutide is still on that list, while the FDA lifted its shortage ...
Results from a recent survey have prompted questions about the influence of GLP-1s on the obesity rate of U.S. adults.
Two new studies identified additional benefits of medications like semaglutide—the active ingredient in Novo Nordisk's ...
A recent meta-analysis of 69 clinical trials found the risk for ischemic optic neuropathy from GLP-1 therapy is too low to be ...
Glucagon-like peptide-1 receptor agonists (GLP-1 RAs) reduce the risk for clinically important kidney and cardiovascula ...
Semaglutide, a GLP-1 agonist, has been widely studied due to its versatility, efficacy, and ability to address multiple ...
As drugs like Ozempic and Wegovy keep flying off the shelves, more and more people are taking the drug into their own hands ...
A study reveals that weight loss can lead to significant healthcare savings, with 7% savings for a 5% BMI reduction and 30% ...
The use of GLP-1s is linked to improved inflammatory bowel disease outcomes in patients with concomitant inflammatory bowel ...